No company wants to spend millions of dollars on a protocol, only to receive a negative result at the end of the trial. Nevertheless, that’s exactly what’s happening time and again in the pharmaceutical industry. But what if you could know earlier if your initial assumptions and expectations were off, and you had an opportunity to correct them? The good news is that you can.
Adaptive and Flexible Trial Designs give biopharmaceutical companies the opportunity to reduce the risk of failure by evaluating interim data analysis at pre-defined points and adapting the study design parameters accordingly, in order to optimize the outcome.